How long should a patient discontinue apixaban (Eliquis) before undergoing a paracentesis?

Apixaban Hold Duration Before Paracentesis

For paracentesis, hold Eliquis (apixaban) for 48-72 hours (2-3 days) before the procedure, with the last dose taken 3 days prior to the procedure.

Risk Classification and Management Strategy

Paracentesis is classified as a high-bleeding risk procedure when considering anticoagulation management. While historically considered low-risk, recent evidence demonstrates significantly elevated bleeding rates when performed on patients taking apixaban 1.

Standard Approach for Normal Renal Function

The last dose of apixaban should be taken 3 days (72 hours) before paracentesis 2. This translates to:

• If procedure is scheduled for Monday morning, last dose should be Friday morning
• Skip all doses on Saturday, Sunday, and Monday morning

The FDA label supports discontinuation at least 48 hours prior to procedures with moderate or high bleeding risk 3, but the more conservative 72-hour window from gastroenterology guidelines is preferable given paracentesis-specific bleeding data.

Modified Approach for Renal Impairment

Patients with CrCl or eGFR 30-50 mL/min require NO dose adjustment for apixaban specifically (unlike dabigatran which requires 5-day hold) 2. However, if renal function is rapidly deteriorating, consult hematology 2.

Patients with CrCl <30 mL/min warrant individualized assessment, as apixaban clearance is significantly impaired 4.

Critical Safety Considerations

High-Risk Scenarios Requiring Extra Caution

Recent data shows paracentesis bleeding rates of 5.5% overall and 2.5% procedure-related in apixaban-exposed patients—substantially higher than historical estimates 1. Specific high-risk factors include:

• Apixaban taken within 6 hours of procedure: 16% bleeding rate 1
• High-dose apixaban (10 mg twice daily): 38% bleeding rate 1
• Concurrent antiplatelet/anticoagulant therapy: 19% bleeding rate 1
• Inpatient status: 5.1% bleeding rate vs lower outpatient risk 1

No Bridging Required

Do not bridge with LMWH or other anticoagulants during the 48-72 hour interruption period 5, 3. The PAUSE trial demonstrated safety of standardized interruption without bridging, with arterial thromboembolism rates of only 0.16% 5.

Resumption After Procedure

Restart apixaban when adequate hemostasis is established 3, typically:

• 2-3 days after high-bleeding risk procedures like paracentesis 2
• Ensure no ongoing bleeding or hematoma expansion
• Resume at the patient's usual maintenance dose

Practical Algorithm

1. Classify bleeding risk: Paracentesis = high-risk procedure
2. Check renal function: CrCl or eGFR
3. Calculate hold duration:
   • Normal renal function (CrCl >50): Last dose 3 days before
   • CrCl 30-50: Last dose 3 days before (same as normal)
   • CrCl <30: Consider longer hold, consult hematology
4. Verify no concurrent anticoagulants/antiplatelets
5. Do NOT bridge with heparin
6. Restart 2-3 days post-procedure when hemostasis confirmed

Common Pitfalls to Avoid

• Don't rely on the 24-hour hold recommended for low-risk procedures—paracentesis is high-risk
• Don't check INR or aPTT to assess apixaban levels; these are unreliable 2
• Don't assume paracentesis is low-risk based on older literature—contemporary data with DOACs shows higher bleeding rates 1
• Don't restart too early—wait for confirmed hemostasis, typically 48-72 hours post-procedure

The evidence strongly supports a conservative 72-hour pre-procedure hold for apixaban before paracentesis, based on both procedural bleeding risk classification 2 and procedure-specific bleeding data 1.